Match!
Diabetes, Obesity and Metabolism
IF
6.13
Papers
3632
Papers 4134
1 page of 414 pages (4,134 results)
Newest
#1Nicklas Järvelä Johansen (UCPH: University of Copenhagen)H-Index: 1
#2Thomas Fremming Dejgaard (UCPH: University of Copenhagen)H-Index: 7
Last. Henrik U. Andersen (Steno Diabetes Center)H-Index: 21
view all 11 authors...
AIMS To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. MATERIALS AND METHODS In a randomized, double-blind, parallel-group trial, 108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy with a body mass index >22.0 kg/m2 and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandia...
Source
#1Ruth E. BrownH-Index: 9
#2Peter G. Bech (Novo Nordisk)H-Index: 2
Last. Ronnie AronsonH-Index: 17
view all 3 authors...
AIMS This study investigated real-world short-term clinical outcomes in adults with type 2 diabetes (T2D) who initiated semaglutide in a specialist endocrinology practice in Canada. MATERIALS AND METHODS This study was a retrospective observational study using data from the Canadian LMC Diabetes Registry. Adults with T2D who were naive to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, a...
Source
#1Luigi F. Meneghini (UTSW: University of Texas Southwestern Medical Center)H-Index: 26
#2Lawrence Blonde (Ochsner Medical Center)H-Index: 37
Last. Timothy S. BaileyH-Index: 25
view all 7 authors...
AIMS ACHIEVE Control, a prospective pragmatic randomised real-life study in insulin-naive adults with type 2 diabetes (T2D), demonstrated statistical superiority of insulin glargine 300 U/mL (Gla-300) over first-generation standard-of-care basal insulin analogues (SOC-BI; insulin glargine 100 U/mL or insulin detemir) for the primary composite endpoint of individualised HbA1c target achievement without documented symptomatic (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia at 6 months. Here, we ...
Source
#1Sandrine Major (McGill University)
#2Anas El Fathi (McGill University)H-Index: 3
Last. Ahmad Haidar (McGill University)H-Index: 22
view all 8 authors...
Conventional bolus calculators apply negative prandial corrections when premeal glucose levels are low. However, no study has evaluated the need for this negative correction with closed-loop systems. We analysed data retrospectively from a cohort study evaluating a closed-loop artificial pancreas system conducted in a diabetes camp over a period of 11 days. Meal boluses with negative correction (n = 98) of 47 participants aged 8 to 22 years were examined. If there was no insulin-on-board from pr...
Source
#1Afroditi Tripyla (University of Bern)H-Index: 1
#2David Herzig (University of Bern)H-Index: 5
Last. Lia Bally (University of Bern)H-Index: 9
view all 9 authors...
We assessed the performance of the factory-calibrated, sixth-generation continuous glucose monitoring (CGM) system Dexcom G6® (DexCom Inc., San Diego, California) during elective abdominal surgery. Twenty adults with (pre)diabetes undergoing abdominal surgery (>2 hours; 15 men, age 69 ± 13 years, glycated haemoglobin 53 ± 14 mmol/mol) wore the sensor from 1 week prior to surgery until hospital discharge. From induction of anaesthesia until 2 hours post-surgery, reference capillary glucose values...
1 CitationsSource
#1Brian E. Ford (Newcastle University)
#2Shruti S. Chachra (Newcastle University)H-Index: 1
Last. Loranne Agius (Newcastle University)H-Index: 37
view all 10 authors...
AIM Small molecule glucokinase activators (GKAs) were developed as potential blood glucose lowering drugs for type 2 diabetes. However, some GKAs showed a decline in glycaemic efficacy during prolonged clinical trials. The proposed mechanisms remain speculative. We tested the hypothesis that GKAs induce hepatic adaptations that alter intra-hepatocyte metabolite homeostasis. METHODS C57BL/6 mice on standard rodent diet were treated with a GKA (AZD1656) acutely or chronically. Hepatocytes were iso...
Source
#1Shweta Urva (Eli Lilly and Company)H-Index: 2
#2Tamer Coskun (Eli Lilly and Company)H-Index: 17
Last. Axel Haupt (Eli Lilly and Company)H-Index: 14
view all 10 authors...
OBJECTIVE The effect of dual GIP and GLP-1 receptor agonist (RA), tirzepatide, on gastric emptying (GE) was compared to that of GLP-1RA in nonclinical and clinical studies. MATERIALS AND METHODS GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Subjects (with and without T2DM) from a Phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo. GE was assessed by acetaminophe...
Source
#1Ruth E. BrownH-Index: 9
#2Peter G. BechH-Index: 2
Last. Ronnie AronsonH-Index: 17
view all 3 authors...
Source
#1Thomas Danne (MHH: Hannover Medical School)H-Index: 6
#2Munehide Matsuhisa (University of Tokushima)H-Index: 43
Last. Geremia B. BolliH-Index: 49
view all 7 authors...
Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes (T1DM) and new generation basal insulins may improve patient outcomes. This post-hoc meta-analysis explored the risk of SH with insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in a pooled population with T1DM from three randomised, multicentre, 6-month similarly designed phase 3 trials: EDITION 4, EDITION JP 1, and EDITION JUNIOR. Endpoints included incidence and time to first occurrence of SH. Am...
Source
#1Maria S. Svane (UCPH: University of Copenhagen)H-Index: 9
#2Helle Hjorth Johannesen (UCPH: University of Copenhagen)H-Index: 11
Last. Thomas Levin Klausen (UCPH: University of Copenhagen)H-Index: 15
view all 16 authors...
AIMS Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for treatment of type 2 diabetes and obesity. No definite link to pancreatitis or pancreatic cancer has been observed with GLP-1RAs, but plasma concentrations of lipase and amylase are increased during treatment. Expansion of the pancreatic volume due to increased DNA synthesis and/or protein synthesis was reported in rodents. We investigated the effect of a GLP-1RA, liraglutide, on pancreatic volume, edema, cellularity and DNA s...
Source
12345678910
Top fields of study
Endocrinology
Type 2 diabetes
Insulin
Diabetes mellitus
Medicine